Reuters logo
BRIEF-Tetraphase pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of Eravacycline in cIAI
October 14, 2016 / 12:13 PM / a year ago

BRIEF-Tetraphase pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of Eravacycline in cIAI

Oct 14 (Reuters) - Tetraphase Pharmaceuticals Inc :

* Tetraphase Pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of eravacycline in cIAI

* Tetraphase Pharmaceuticals Inc - top-line IGNITE4 data expected in 4Q 2017

* Tetraphase Pharmaceuticals Inc- study is expected to enroll approximately 450 adult patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below